Nandrolone and stanozolol

Heavy consumption of the essential amino acid lysine (as indicated in the treatment of cold sores) has allegedly shown false positives in some and was cited by American shotputter C. J. Hunter as the reason for his positive test, though in 2004 he admitted to a federal grand jury that he had injected nandrolone. [32] A possible cause of incorrect urine test results is the presence of metabolites from other AAS, though modern urinalysis can usually determine the exact AAS used by analyzing the ratio of the two remaining nandrolone metabolites. As a result of the numerous overturned verdicts, the testing procedure was reviewed by UK Sport . On October 5, 2007, three-time Olympic gold medalist for track and field Marion Jones admitted to use of the drug, and was sentenced to six months in jail for lying to a federal grand jury in 2000. [33]

The use of Stanozolol will suppress natural testosterone production in all men and should only be used in conjunction with exogenous testosterone. Failure to supplement with exogenous testosterone will put the man into a low testosterone state. The form of testosterone is inconsequential.

Once all Stanozolol use is ended and any and all anabolic steroids have cleared the body natural testosterone production will begin again. It will not occur overnight and it is recommended that a Post Cycle Therapy (PCT) plan follow use. A PCT plan will aid in recovery. A PCT plan will not complete recovery, this will still take several months, but it will speed up the process and increase the odds of a successful recovery.

Important Note: Women do not need to supplement with testosterone during Stanozolol use.

Important Note: Natural testosterone recovery assumes no damage was done to the Hypothalamic-Pituitary-Testicular-Axis (HPTA) during use and that no prior low testosterone condition existed prior to use.

Several substances such as anabolic androgenic steroids (AAS), peptide hormones like insulin-like growth factor-I (IGF-I), aromatase inhibitors and estrogen antagonists are offered via the Internet, and are assumed without considering the potential deleterious effects that can be caused by their administration. In this study we aimed to determine if nandrolone and stanozolol, two commonly used AAS, could have an effect on Leydig cell tumor proliferation and if their effects could be potentiated by the concomitant use of IGF-I. Using a rat Leydig tumor cell line, R2C cells, as experimental model we found that nandrolone and stanozolol caused a dose-dependent induction of aromatase expression and estradiol (E2) production. When used in combination with IGF-I they were more effective than single molecules in inducing aromatase expression. AAS exhibited estrogenic activity and induced rapid estrogen receptor (ER)-dependent pathways involving IGF1R, AKT, and ERK1/2 phosphorylation. Inhibitors for these kinases decreased AAS-dependent aromatase expression. Up-regulated aromatase levels and related E2 production increased cell proliferation as a consequence of increased cyclin E expression. The observation that ER antagonist ICI182,780 was also able to significantly reduce ASS- and AAS + IGF-induced cell proliferation, confirmed a role for estrogens in AAS-dependent proliferative effects. Taken together these data clearly indicate that the use of high doses of AAS, as it occurs in doping practice, enhances Leydig cell proliferation, increasing the risk of tumor development. This risk is higher when AAS are used in association with IGF-I. To our knowledge this is the first report directly associating AAS and testicular cancer. J. Cell. Physiol. 227: 2079–2088, 2012. © 2011 Wiley Periodicals, Inc.

Nandrolone and stanozolol

nandrolone and stanozolol


nandrolone and stanozololnandrolone and stanozololnandrolone and stanozololnandrolone and stanozololnandrolone and stanozolol